Published in Eur J Clin Pharmacol on December 02, 2003
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med (2011) 2.43
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med (2007) 2.02
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.49
Salivary cotinine concentration versus self-reported cigarette smoking: Three patterns of inconsistency in adolescence. Nicotine Tob Res (2006) 1.47
Applications of CYP450 testing in the clinical setting. Mol Diagn Ther (2013) 1.08
Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci (2005) 1.04
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin Neurosci (2009) 0.89
Pharmacogenomics of suicidal events. Pharmacogenomics (2010) 0.87
Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol (2010) 0.86
Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna) (2014) 0.85
Pharmacogenetics of anxiolytic drugs. J Neural Transm (Vienna) (2009) 0.83
Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis. PLoS One (2011) 0.82
Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. J Neural Transm (Vienna) (2014) 0.80
Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions. Eur J Clin Pharmacol (2004) 0.80
Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Med (2014) 0.80
Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. Eur J Clin Pharmacol (2010) 0.79
Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med (2010) 0.77
Worldwide distribution of cytochrome P450 alleles: A meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther (2017) 0.77
CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig (2013) 0.76
Pharmacogenetics of antipsychotic treatment response and side effects. Therapy (2010) 0.75
High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies. Pharmacogenomics J (2016) 0.75
The association between CYP2D6 genotype and switching antipsychotic medication to clozapine. Eur J Clin Pharmacol (2013) 0.75
Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol (1967) 22.39
A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry (1978) 12.65
Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal (1999) 9.80
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
Hamilton Depression Rating Scale. Extracted from Regular and Change Versions of the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry (1981) 1.68
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther (1992) 1.66
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol (2002) 1.52
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics (1996) 1.17
Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther (1995) 1.15
Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene (1999) 1.11
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) (1999) 0.95
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics (1999) 0.91
Outcome of depression in psychiatric settings. Br J Psychiatry (1994) 0.90
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics (1999) 0.86
Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics (1998) 0.86
DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum Genet (1994) 0.85
Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics (1999) 0.82
A patient with treatment-resistant schizophrenia and cytochrome P4502D6 gene duplication. Clin Genet (2002) 0.81
Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. Pharmacopsychiatry (1998) 0.78
Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol (1999) 0.77
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther (2006) 3.09
Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit (2004) 2.84
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics (2006) 1.80
Ultrasmall monodisperse NaYF(4):Yb(3+)/Tm(3+) nanocrystals with enhanced near-infrared to near-infrared upconversion photoluminescence. ACS Nano (2010) 1.76
[More stringent requirements concerning manuscripts. Declarations of potential connections and conflicts of interest published in the Lakartidningen]. Lakartidningen (2002) 1.74
(α-NaYbF4:Tm(3+))/CaF2 core/shell nanoparticles with efficient near-infrared to near-infrared upconversion for high-contrast deep tissue bioimaging. ACS Nano (2012) 1.61
Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos (2013) 1.59
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics (2008) 1.52
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol (2008) 1.48
Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet (2011) 1.42
Intense visible and near-infrared upconversion photoluminescence in colloidal LiYF₄:Er³+ nanocrystals under excitation at 1490 nm. ACS Nano (2011) 1.39
[Fatigue and its causes--who governs the connection?]. Lakartidningen (2008) 1.38
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther (2005) 1.35
Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health (2007) 1.32
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol (2011) 1.24
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol (2008) 1.22
Ramus or chin grafts for maxillary sinus inlay and local onlay augmentation: comparison of donor site morbidity and complications. Clin Implant Dent Relat Res (2003) 1.21
A clinical and histologic evaluation of implant integration in the posterior maxilla after sinus floor augmentation with autogenous bone, bovine hydroxyapatite, or a 20:80 mixture. Int J Oral Maxillofac Implants (2002) 1.18
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One (2013) 1.17
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun (2005) 1.15
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun (2002) 1.15
Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther (2003) 1.14
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol (2007) 1.13
Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol (2007) 1.11
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics (2003) 1.11
Reconstruction of the atrophic edentulous maxilla with free iliac crest grafts and implants: a 3-year report of a prospective clinical study. Clin Implant Dent Relat Res (2007) 1.11
Bone reformation and implant integration following maxillary sinus membrane elevation: an experimental study in primates. Clin Implant Dent Relat Res (2006) 1.11
The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther (2003) 1.09
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol (2008) 1.08
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol (2003) 1.08
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics (2006) 1.06
Effect of caffeine exposure during pregnancy on birth weight and gestational age. Am J Epidemiol (2002) 1.05
Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol (2003) 1.05
Core/shell NaGdF4:Nd(3+)/NaGdF4 nanocrystals with efficient near-infrared to near-infrared downconversion photoluminescence for bioimaging applications. ACS Nano (2012) 1.04
Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res (2004) 1.04
Detection of major depression in Ugandan primary health care settings using simple questions from a subjective well-being (SWB) subscale. Soc Psychiatry Psychiatr Epidemiol (2006) 1.04
Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br J Clin Pharmacol (2008) 1.01
Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J (2009) 1.00
A prospective 1-year clinical and radiographic study of implants placed after maxillary sinus floor augmentation with bovine hydroxyapatite and autogenous bone. J Oral Maxillofac Surg (2002) 1.00
TLX activates MASH1 for induction of neuronal lineage commitment of adult hippocampal neuroprogenitors. Mol Cell Neurosci (2010) 0.99
A longitudinal study of PTSD in a sample of adult mass-evacuated Kosovars, some of whom returned to their home country. Eur Psychiatry (2006) 0.99
Sinus bone formation and implant survival after sinus membrane elevation and implant placement: a 1- to 6-year follow-up study. Clin Oral Implants Res (2011) 0.99
Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl) (2005) 0.98
Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol (2005) 0.97
Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol (2006) 0.96
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol (2005) 0.95
Maxillary sinus augmentation using sinus membrane elevation and peripheral venous blood for implant-supported rehabilitation of the atrophic posterior maxilla: case series. Clin Implant Dent Relat Res (2007) 0.94
Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol (2003) 0.94
Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol (2007) 0.93
Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. Pharmacogenet Genomics (2009) 0.93
MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol (2009) 0.93
Donor site morbidity in two different approaches to anterior iliac crest bone harvesting. Clin Implant Dent Relat Res (2003) 0.92
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol (2005) 0.92
CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol (2008) 0.91
Adaptation of the multidimensional scale of perceived social support in a Ugandan setting. Afr Health Sci (2009) 0.91
Sense of coherence and social support in relation to recovery in first-episode patients with major depression: a one-year prospective study. Int J Ment Health Nurs (2005) 0.91
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol (2010) 0.91
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol (2007) 0.90
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol (2003) 0.90
Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol (2007) 0.89
Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol (2004) 0.89
Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol (2003) 0.89
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther (2002) 0.89
The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol (2002) 0.88
Metabolism and elimination of quinine in healthy volunteers. Eur J Clin Pharmacol (2003) 0.88
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther (2002) 0.88
Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics (2002) 0.87
Life events associated with major depression in Ugandan primary healthcare (PHC) patients: issues of cultural specificity. Int J Soc Psychiatry (2008) 0.86
Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics (2006) 0.86
Calculations of two-photon charge-transfer excitations using Coulomb-attenuated density-functional theory. J Chem Phys (2005) 0.86
Effects of conjugation length, electron donor and acceptor strengths on two-photon absorption cross sections of asymmetric zinc-porphyrin derivatives. J Chem Phys (2006) 0.86
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol (2010) 0.86
Searching of potential energy curves for the benzene dimer using dispersion-corrected density functional theory. Phys Chem Chem Phys (2008) 0.85
The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol (2005) 0.85
Sinus membrane elevation and simultaneous insertion of dental implants: a new surgical technique in maxillary sinus floor augmentation. Periodontol 2000 (2008) 0.85
Oxidized titanium implants (Nobel Biocare TiUnite) compared with turned titanium implants (Nobel Biocare mark III) with respect to implant failure in a group of consecutive patients treated with early functional loading and two-stage protocol. Clin Oral Implants Res (2005) 0.85
Density functional theory study of vibronic structure of the first absorption Qx band in free-base porphin. Spectrochim Acta A Mol Biomol Spectrosc (2006) 0.85
Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur J Clin Pharmacol (2007) 0.85
Two-photon absorption in solution by means of time-dependent density-functional theory and the polarizable continuum model. J Chem Phys (2005) 0.85
Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol (2003) 0.85
Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. J Clin Pharmacol (2011) 0.84
Demystifying the solvatochromic reversal in Brooker's merocyanine dye. Phys Chem Chem Phys (2010) 0.84
Polarization propagator for x-ray spectra. Phys Rev Lett (2006) 0.83
The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol (2012) 0.83
Density functional response theory calculations of three-photon absorption. J Chem Phys (2004) 0.83
Conformations, structural transitions and visible near-infrared absorption spectra of four-, five- and six-coordinated Cu(II) aqua complexes. Phys Chem Chem Phys (2008) 0.83
Cubic nonlinear optical properties of platinum-terminated polyynediyl chains. Inorg Chem (2008) 0.83
Computer simulations of aqua metal ions for accurate reproduction of hydration free energies and structures. J Chem Phys (2010) 0.82
Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care (2006) 0.82
Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role? Physiol Behav (2007) 0.82
Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob Agents Chemother (2006) 0.82
Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. Basic Clin Pharmacol Toxicol (2014) 0.82
Density functional theory for hyperfine coupling constants with the restricted-unrestricted approach. J Chem Phys (2004) 0.81
Identifying predictors for good lithium response - a retrospective analysis of 100 patients with bipolar disorder using a life-charting method. Eur Psychiatry (2009) 0.81
Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol (2005) 0.81
Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. J Affect Disord (2004) 0.81
A histomorphometric comparison of the bone graft-titanium interface between interpositional and onlay/inlay bone grafting techniques. Int J Oral Maxillofac Implants (2006) 0.81
High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS (2013) 0.81
Patterns of sensitisation in the course of affective illness. A life-charting study of treatment-refractory depressed patients. J Affect Disord (2002) 0.81
Two-photon absorption cross-sections of reference dyes: a critical examination. Chemphyschem (2008) 0.81